Robbins LLP Encourages SLNO Stockholders to Contact the Firm for Information About the Class Action

Robbins LLP is encouraging stockholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO) to contact the firm regarding a class action lawsuit. The lawsuit alleges that Soleno Therapeutics misled investors about the safety and efficacy of its drug, DCCR, for Prader-Willi syndrome, citing concerns about fluid retention and adverse events. The complaint details stock declines following reports of an exposé on clinical trial issues, a patient death, and reduced DCCR launch trajectory due to community concerns.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin